Stearoyl-CoA Desaturase 1 as a Therapeutic Target for the Treatment of Cancer
A distinctive feature of cancer cells of various origins involves alterations of the composition of lipids, with significant enrichment in monounsaturated fatty acids. These molecules, in addition to being structural components of newly formed cell membranes of intensely proliferating cancer cells,...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2019-07-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/11/7/948 |
| _version_ | 1797761975744200704 |
|---|---|
| author | Zuzanna Tracz-Gaszewska Pawel Dobrzyn |
| author_facet | Zuzanna Tracz-Gaszewska Pawel Dobrzyn |
| author_sort | Zuzanna Tracz-Gaszewska |
| collection | DOAJ |
| description | A distinctive feature of cancer cells of various origins involves alterations of the composition of lipids, with significant enrichment in monounsaturated fatty acids. These molecules, in addition to being structural components of newly formed cell membranes of intensely proliferating cancer cells, support tumorigenic signaling. An increase in the expression of stearoyl-CoA desaturase 1 (SCD1), the enzyme that converts saturated fatty acids to ∆9-monounsaturated fatty acids, has been observed in a wide range of cancer cells, and this increase is correlated with cancer aggressiveness and poor outcomes for patients. Studies have demonstrated the involvement of SCD1 in the promotion of cancer cell proliferation, migration, metastasis, and tumor growth. Many studies have reported a role for this lipogenic factor in maintaining the characteristics of cancer stem cells (i.e., the population of cells that contributes to cancer progression and resistance to chemotherapy). Importantly, both the products of SCD1 activity and its direct impact on tumorigenic pathways have been demonstrated. Based on these findings, SCD1 appears to be a significant player in the development of malignant disease and may be a promising target for anticancer therapy. Numerous chemical compounds that exert inhibitory effects on SCD1 have been developed and preclinically tested. The present review summarizes our current knowledge of the ways in which SCD1 contributes to the progression of cancer and discusses opportunities and challenges of using SCD1 inhibitors for the treatment of cancer. |
| first_indexed | 2024-03-12T19:20:47Z |
| format | Article |
| id | doaj.art-4b543ef29a3c4031977a804f0b2e1f8f |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-12T19:20:47Z |
| publishDate | 2019-07-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-4b543ef29a3c4031977a804f0b2e1f8f2023-08-02T05:09:11ZengMDPI AGCancers2072-66942019-07-0111794810.3390/cancers11070948cancers11070948Stearoyl-CoA Desaturase 1 as a Therapeutic Target for the Treatment of CancerZuzanna Tracz-Gaszewska0Pawel Dobrzyn1Laboratory of Molecular Medical Biochemistry, Nencki Institute of Experimental Biology Polish Academy of Sciences, 02-093 Warsaw, PolandLaboratory of Molecular Medical Biochemistry, Nencki Institute of Experimental Biology Polish Academy of Sciences, 02-093 Warsaw, PolandA distinctive feature of cancer cells of various origins involves alterations of the composition of lipids, with significant enrichment in monounsaturated fatty acids. These molecules, in addition to being structural components of newly formed cell membranes of intensely proliferating cancer cells, support tumorigenic signaling. An increase in the expression of stearoyl-CoA desaturase 1 (SCD1), the enzyme that converts saturated fatty acids to ∆9-monounsaturated fatty acids, has been observed in a wide range of cancer cells, and this increase is correlated with cancer aggressiveness and poor outcomes for patients. Studies have demonstrated the involvement of SCD1 in the promotion of cancer cell proliferation, migration, metastasis, and tumor growth. Many studies have reported a role for this lipogenic factor in maintaining the characteristics of cancer stem cells (i.e., the population of cells that contributes to cancer progression and resistance to chemotherapy). Importantly, both the products of SCD1 activity and its direct impact on tumorigenic pathways have been demonstrated. Based on these findings, SCD1 appears to be a significant player in the development of malignant disease and may be a promising target for anticancer therapy. Numerous chemical compounds that exert inhibitory effects on SCD1 have been developed and preclinically tested. The present review summarizes our current knowledge of the ways in which SCD1 contributes to the progression of cancer and discusses opportunities and challenges of using SCD1 inhibitors for the treatment of cancer.https://www.mdpi.com/2072-6694/11/7/948lipid metabolismstearoyl-CoA desaturase 1 (SCD1)monounsaturated fatty acidsSCD1 inhibitorstargeted therapy |
| spellingShingle | Zuzanna Tracz-Gaszewska Pawel Dobrzyn Stearoyl-CoA Desaturase 1 as a Therapeutic Target for the Treatment of Cancer Cancers lipid metabolism stearoyl-CoA desaturase 1 (SCD1) monounsaturated fatty acids SCD1 inhibitors targeted therapy |
| title | Stearoyl-CoA Desaturase 1 as a Therapeutic Target for the Treatment of Cancer |
| title_full | Stearoyl-CoA Desaturase 1 as a Therapeutic Target for the Treatment of Cancer |
| title_fullStr | Stearoyl-CoA Desaturase 1 as a Therapeutic Target for the Treatment of Cancer |
| title_full_unstemmed | Stearoyl-CoA Desaturase 1 as a Therapeutic Target for the Treatment of Cancer |
| title_short | Stearoyl-CoA Desaturase 1 as a Therapeutic Target for the Treatment of Cancer |
| title_sort | stearoyl coa desaturase 1 as a therapeutic target for the treatment of cancer |
| topic | lipid metabolism stearoyl-CoA desaturase 1 (SCD1) monounsaturated fatty acids SCD1 inhibitors targeted therapy |
| url | https://www.mdpi.com/2072-6694/11/7/948 |
| work_keys_str_mv | AT zuzannatraczgaszewska stearoylcoadesaturase1asatherapeutictargetforthetreatmentofcancer AT paweldobrzyn stearoylcoadesaturase1asatherapeutictargetforthetreatmentofcancer |